GUBRA: CRO profitability surged as obesity programs advanced and GUB-UCN2 entered clinical testing
TradingView GUBRA: CRO profitability surged as obesity programs advanced and GUB-UCN2 entered clinical testing Partnered obesity programs advanced to Phase 2, and GUB-UCN2 entered Phase 1/2a. CRO Q3 revenue grew 6% QoQ and YoY as its adjusted EBIT margin rose to 25%; 2026 CRO guidance was…